BFK Stock Overview
An investment holding company, research, develops, produces, packages, sells, and markets western medicines and traditional Chinese medicine (TCM) formulated products for hospitals and medical institutions in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Pharmesis International Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | S$0.59 |
| 52 Week High | S$0.70 |
| 52 Week Low | S$0.065 |
| Beta | -0.60 |
| 1 Month Change | -8.53% |
| 3 Month Change | 379.67% |
| 1 Year Change | 502.04% |
| 3 Year Change | 293.33% |
| 5 Year Change | 174.42% |
| Change since IPO | -84.87% |
Recent News & Updates
Recent updates
Shareholder Returns
| BFK | SG Pharmaceuticals | SG Market | |
|---|---|---|---|
| 7D | -1.7% | -0.8% | -2.1% |
| 1Y | 502.0% | 9.2% | 12.3% |
Return vs Industry: BFK exceeded the SG Pharmaceuticals industry which returned 9.2% over the past year.
Return vs Market: BFK exceeded the SG Market which returned 12.3% over the past year.
Price Volatility
| BFK volatility | |
|---|---|
| BFK Average Weekly Movement | 26.2% |
| Pharmaceuticals Industry Average Movement | 6.2% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in SG Market | 13.5% |
| 10% least volatile stocks in SG Market | 1.9% |
Stable Share Price: BFK's share price has been volatile over the past 3 months compared to the SG market.
Volatility Over Time: Insufficient data to determine BFK's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | n/a | Xuedan Wu | www.pharmesis.com |
Pharmesis International Ltd., an investment holding company, research, develops, produces, packages, sells, and markets western medicines and traditional Chinese medicine (TCM) formulated products for hospitals and medical institutions in the People’s Republic of China. The company provides prescribed products and over-the-counter drugs. It offers western medicine products under the Kinna brand, including Anethole Trithione for the treatment of illness relating to the liver and gall bladder; Compound Procaine hydrochloride to treat arteriosclerosi, menopausal symptoms, dyspepsia, and adynamia; Lianpushuangqing for acute inflammation; AFenKa to treat migraine, pain, headache, nasosinusitis, cold, muscle pain, menstrual pain, toothache, and arthritis; Xiao Shi Jian Pi to treat flatus, inappetency, dyspepsy, and spleen weakness; and Xiao Luo Tong for the rheumatoid arthritis and other rheumatic diseases treatment.
Pharmesis International Ltd. Fundamentals Summary
| BFK fundamental statistics | |
|---|---|
| Market cap | S$18.70m |
| Earnings (TTM) | -S$1.37m |
| Revenue (TTM) | S$7.77m |
2.4x
P/S Ratio-13.6x
P/E RatioIs BFK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BFK income statement (TTM) | |
|---|---|
| Revenue | CN¥41.81m |
| Cost of Revenue | CN¥29.34m |
| Gross Profit | CN¥12.47m |
| Other Expenses | CN¥19.87m |
| Earnings | -CN¥7.40m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.23 |
| Gross Margin | 29.82% |
| Net Profit Margin | -17.69% |
| Debt/Equity Ratio | 28.4% |
How did BFK perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 06:09 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Pharmesis International Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|